Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze
This study investigated the interplay of cholecystokinin (CCK) and endogenous opioid peptides in the regulation of anxiety. The acute administration of non-selective CCK agonist caerulein (1 and 5 μg/kg) and a selective CCK B receptor agonist BOC-CCK-4 (1, 10 and 50 μg/kg) induced a dose-dependent a...
Gespeichert in:
| Veröffentlicht in: | Neuropeptides (Edinburgh) 1998-06, Vol.32 (3), p.235-240 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 240 |
|---|---|
| container_issue | 3 |
| container_start_page | 235 |
| container_title | Neuropeptides (Edinburgh) |
| container_volume | 32 |
| creator | Kõks, S Soosaar, A Võikar, V Volke, V Ustav, M Männistö, P.T Bourin, M Vasar, E |
| description | This study investigated the interplay of cholecystokinin (CCK) and endogenous opioid peptides in the regulation of anxiety. The acute administration of non-selective CCK agonist caerulein (1 and 5 μg/kg) and a selective CCK
B receptor agonist BOC-CCK-4 (1, 10 and 50 μg/kg) induced a dose-dependent anxiogenic-like action in the plus-maze model of anxiety. BOC-CCK-4 displayed a similar efficacy with caerulein, indicating that the described effect was mediated via CCK
B receptor subtype. The opioid antagonist naloxone itself (0.5 mg/kg) did not change the exploratory activity of rats in the plus-maze. However, the combination of naloxone with the sub-effective doses of caerulein (1 μg/kg) and BOC-CCK-4 (1 μg/kg) induced a significant inhibition of exploratory behaviour in rats. Accordingly, CCK and endogenous opioid peptides have an antagonistic role in the exploratory model of anxiety in rats. |
| doi_str_mv | 10.1016/S0143-4179(98)90042-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16519143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0143417998900427</els_id><sourcerecordid>16519143</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-a7df2c61c4687f380c07b64ed2542dc734bd37026b0ccf42b1dec37b5e03eeb53</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EokvhJ4B8QAgOAdtx4uSEUMWXVKkH4Gw540kZ6rVD7K1afj3e7qrixskj-XnfGT2MPZfirRSyf_dNSN02Wprx9Ti8GYXQqjEP2EZ2rWqUGbqHbHOPnLAnOf8Se2gYHrOT2jCMojMbli4WSuS5i8Vdpki58OhCukkR-ZIKxkKuYK7_N5QuMRI0ga6QOyiUIk8zh58pINzmkq4oUuTHmszrjAGva9zzJexys3V_8Cl7NLuQ8dnxPWU_Pn38fvalOb_4_PXsw3kDWsnSOONnBb0E3Q9mbgcBwky9Rq86rTyYVk--NUL1kwCYtZqkR2jN1KFoEaeuPWWvDr3Lmn7vMBe7pQwYgouYdtnKvpNj1VPB7gDCmnJecbbLSlu33lop7N60vTNt9xrtONg709bU3Ivjgt20Rf9P6qC2Ai-PgMvgwry6CJTvOaWMMv3-0PcHDKuNa8LVZiCMgJ5WhGJ9ov9c8hfluJ1t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16519143</pqid></control><display><type>article</type><title>Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kõks, S ; Soosaar, A ; Võikar, V ; Volke, V ; Ustav, M ; Männistö, P.T ; Bourin, M ; Vasar, E</creator><creatorcontrib>Kõks, S ; Soosaar, A ; Võikar, V ; Volke, V ; Ustav, M ; Männistö, P.T ; Bourin, M ; Vasar, E</creatorcontrib><description>This study investigated the interplay of cholecystokinin (CCK) and endogenous opioid peptides in the regulation of anxiety. The acute administration of non-selective CCK agonist caerulein (1 and 5 μg/kg) and a selective CCK
B receptor agonist BOC-CCK-4 (1, 10 and 50 μg/kg) induced a dose-dependent anxiogenic-like action in the plus-maze model of anxiety. BOC-CCK-4 displayed a similar efficacy with caerulein, indicating that the described effect was mediated via CCK
B receptor subtype. The opioid antagonist naloxone itself (0.5 mg/kg) did not change the exploratory activity of rats in the plus-maze. However, the combination of naloxone with the sub-effective doses of caerulein (1 μg/kg) and BOC-CCK-4 (1 μg/kg) induced a significant inhibition of exploratory behaviour in rats. Accordingly, CCK and endogenous opioid peptides have an antagonistic role in the exploratory model of anxiety in rats.</description><identifier>ISSN: 0143-4179</identifier><identifier>EISSN: 1532-2785</identifier><identifier>DOI: 10.1016/S0143-4179(98)90042-7</identifier><identifier>PMID: 10189057</identifier><identifier>CODEN: NRPPDD</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Anxiety - chemically induced ; Behavioral psychophysiology ; Biological and medical sciences ; Ceruletide - pharmacology ; Cholecystokinin - agonists ; Disease Models, Animal ; Drug Synergism ; Exploratory Behavior - drug effects ; Fundamental and applied biological sciences. Psychology ; Male ; Naloxone - pharmacology ; Narcotic Antagonists - pharmacology ; Neurotransmission and behavior ; Psychology. Psychoanalysis. Psychiatry ; Psychology. Psychophysiology ; Rats ; Rats, Wistar ; Receptor, Cholecystokinin B ; Receptors, Cholecystokinin - agonists ; Receptors, Cholecystokinin - physiology ; Tetragastrin - analogs & derivatives ; Tetragastrin - pharmacology</subject><ispartof>Neuropeptides (Edinburgh), 1998-06, Vol.32 (3), p.235-240</ispartof><rights>1998</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-a7df2c61c4687f380c07b64ed2542dc734bd37026b0ccf42b1dec37b5e03eeb53</citedby><cites>FETCH-LOGICAL-c421t-a7df2c61c4687f380c07b64ed2542dc734bd37026b0ccf42b1dec37b5e03eeb53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0143-4179(98)90042-7$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2272765$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10189057$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kõks, S</creatorcontrib><creatorcontrib>Soosaar, A</creatorcontrib><creatorcontrib>Võikar, V</creatorcontrib><creatorcontrib>Volke, V</creatorcontrib><creatorcontrib>Ustav, M</creatorcontrib><creatorcontrib>Männistö, P.T</creatorcontrib><creatorcontrib>Bourin, M</creatorcontrib><creatorcontrib>Vasar, E</creatorcontrib><title>Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze</title><title>Neuropeptides (Edinburgh)</title><addtitle>Neuropeptides</addtitle><description>This study investigated the interplay of cholecystokinin (CCK) and endogenous opioid peptides in the regulation of anxiety. The acute administration of non-selective CCK agonist caerulein (1 and 5 μg/kg) and a selective CCK
B receptor agonist BOC-CCK-4 (1, 10 and 50 μg/kg) induced a dose-dependent anxiogenic-like action in the plus-maze model of anxiety. BOC-CCK-4 displayed a similar efficacy with caerulein, indicating that the described effect was mediated via CCK
B receptor subtype. The opioid antagonist naloxone itself (0.5 mg/kg) did not change the exploratory activity of rats in the plus-maze. However, the combination of naloxone with the sub-effective doses of caerulein (1 μg/kg) and BOC-CCK-4 (1 μg/kg) induced a significant inhibition of exploratory behaviour in rats. Accordingly, CCK and endogenous opioid peptides have an antagonistic role in the exploratory model of anxiety in rats.</description><subject>Animals</subject><subject>Anxiety - chemically induced</subject><subject>Behavioral psychophysiology</subject><subject>Biological and medical sciences</subject><subject>Ceruletide - pharmacology</subject><subject>Cholecystokinin - agonists</subject><subject>Disease Models, Animal</subject><subject>Drug Synergism</subject><subject>Exploratory Behavior - drug effects</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Male</subject><subject>Naloxone - pharmacology</subject><subject>Narcotic Antagonists - pharmacology</subject><subject>Neurotransmission and behavior</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychology. Psychophysiology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptor, Cholecystokinin B</subject><subject>Receptors, Cholecystokinin - agonists</subject><subject>Receptors, Cholecystokinin - physiology</subject><subject>Tetragastrin - analogs & derivatives</subject><subject>Tetragastrin - pharmacology</subject><issn>0143-4179</issn><issn>1532-2785</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EokvhJ4B8QAgOAdtx4uSEUMWXVKkH4Gw540kZ6rVD7K1afj3e7qrixskj-XnfGT2MPZfirRSyf_dNSN02Wprx9Ti8GYXQqjEP2EZ2rWqUGbqHbHOPnLAnOf8Se2gYHrOT2jCMojMbli4WSuS5i8Vdpki58OhCukkR-ZIKxkKuYK7_N5QuMRI0ga6QOyiUIk8zh58pINzmkq4oUuTHmszrjAGva9zzJexys3V_8Cl7NLuQ8dnxPWU_Pn38fvalOb_4_PXsw3kDWsnSOONnBb0E3Q9mbgcBwky9Rq86rTyYVk--NUL1kwCYtZqkR2jN1KFoEaeuPWWvDr3Lmn7vMBe7pQwYgouYdtnKvpNj1VPB7gDCmnJecbbLSlu33lop7N60vTNt9xrtONg709bU3Ivjgt20Rf9P6qC2Ai-PgMvgwry6CJTvOaWMMv3-0PcHDKuNa8LVZiCMgJ5WhGJ9ov9c8hfluJ1t</recordid><startdate>19980601</startdate><enddate>19980601</enddate><creator>Kõks, S</creator><creator>Soosaar, A</creator><creator>Võikar, V</creator><creator>Volke, V</creator><creator>Ustav, M</creator><creator>Männistö, P.T</creator><creator>Bourin, M</creator><creator>Vasar, E</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7TK</scope></search><sort><creationdate>19980601</creationdate><title>Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze</title><author>Kõks, S ; Soosaar, A ; Võikar, V ; Volke, V ; Ustav, M ; Männistö, P.T ; Bourin, M ; Vasar, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-a7df2c61c4687f380c07b64ed2542dc734bd37026b0ccf42b1dec37b5e03eeb53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Anxiety - chemically induced</topic><topic>Behavioral psychophysiology</topic><topic>Biological and medical sciences</topic><topic>Ceruletide - pharmacology</topic><topic>Cholecystokinin - agonists</topic><topic>Disease Models, Animal</topic><topic>Drug Synergism</topic><topic>Exploratory Behavior - drug effects</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Male</topic><topic>Naloxone - pharmacology</topic><topic>Narcotic Antagonists - pharmacology</topic><topic>Neurotransmission and behavior</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychology. Psychophysiology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptor, Cholecystokinin B</topic><topic>Receptors, Cholecystokinin - agonists</topic><topic>Receptors, Cholecystokinin - physiology</topic><topic>Tetragastrin - analogs & derivatives</topic><topic>Tetragastrin - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kõks, S</creatorcontrib><creatorcontrib>Soosaar, A</creatorcontrib><creatorcontrib>Võikar, V</creatorcontrib><creatorcontrib>Volke, V</creatorcontrib><creatorcontrib>Ustav, M</creatorcontrib><creatorcontrib>Männistö, P.T</creatorcontrib><creatorcontrib>Bourin, M</creatorcontrib><creatorcontrib>Vasar, E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Neurosciences Abstracts</collection><jtitle>Neuropeptides (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kõks, S</au><au>Soosaar, A</au><au>Võikar, V</au><au>Volke, V</au><au>Ustav, M</au><au>Männistö, P.T</au><au>Bourin, M</au><au>Vasar, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze</atitle><jtitle>Neuropeptides (Edinburgh)</jtitle><addtitle>Neuropeptides</addtitle><date>1998-06-01</date><risdate>1998</risdate><volume>32</volume><issue>3</issue><spage>235</spage><epage>240</epage><pages>235-240</pages><issn>0143-4179</issn><eissn>1532-2785</eissn><coden>NRPPDD</coden><abstract>This study investigated the interplay of cholecystokinin (CCK) and endogenous opioid peptides in the regulation of anxiety. The acute administration of non-selective CCK agonist caerulein (1 and 5 μg/kg) and a selective CCK
B receptor agonist BOC-CCK-4 (1, 10 and 50 μg/kg) induced a dose-dependent anxiogenic-like action in the plus-maze model of anxiety. BOC-CCK-4 displayed a similar efficacy with caerulein, indicating that the described effect was mediated via CCK
B receptor subtype. The opioid antagonist naloxone itself (0.5 mg/kg) did not change the exploratory activity of rats in the plus-maze. However, the combination of naloxone with the sub-effective doses of caerulein (1 μg/kg) and BOC-CCK-4 (1 μg/kg) induced a significant inhibition of exploratory behaviour in rats. Accordingly, CCK and endogenous opioid peptides have an antagonistic role in the exploratory model of anxiety in rats.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>10189057</pmid><doi>10.1016/S0143-4179(98)90042-7</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0143-4179 |
| ispartof | Neuropeptides (Edinburgh), 1998-06, Vol.32 (3), p.235-240 |
| issn | 0143-4179 1532-2785 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16519143 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Anxiety - chemically induced Behavioral psychophysiology Biological and medical sciences Ceruletide - pharmacology Cholecystokinin - agonists Disease Models, Animal Drug Synergism Exploratory Behavior - drug effects Fundamental and applied biological sciences. Psychology Male Naloxone - pharmacology Narcotic Antagonists - pharmacology Neurotransmission and behavior Psychology. Psychoanalysis. Psychiatry Psychology. Psychophysiology Rats Rats, Wistar Receptor, Cholecystokinin B Receptors, Cholecystokinin - agonists Receptors, Cholecystokinin - physiology Tetragastrin - analogs & derivatives Tetragastrin - pharmacology |
| title | Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T00%3A42%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Opioid%20antagonist%20naloxone%20potentiates%20anxiogenic-like%20action%20of%20cholecystokinin%20agonists%20in%20elevated%20plus-maze&rft.jtitle=Neuropeptides%20(Edinburgh)&rft.au=K%C3%B5ks,%20S&rft.date=1998-06-01&rft.volume=32&rft.issue=3&rft.spage=235&rft.epage=240&rft.pages=235-240&rft.issn=0143-4179&rft.eissn=1532-2785&rft.coden=NRPPDD&rft_id=info:doi/10.1016/S0143-4179(98)90042-7&rft_dat=%3Cproquest_cross%3E16519143%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16519143&rft_id=info:pmid/10189057&rft_els_id=S0143417998900427&rfr_iscdi=true |